Assignment: Psychological symbolism

Assignment: Psychological symbolism
Assignment: Psychological symbolism
Permalink:
Assignment: Psychological symbolism
Question 1 (1 point)
When assessing the combination of visual and text in a multimedia presentation, what are you looking for when assessing the grounding?Question 1 options:The visual’s perception of the horizonPlacement of visuals within a textUse of dark colors in the visualWhether the visual is cited from a reliable sourceSave
Question 2 (1 point)
Psychological symbolism refers to all the cultural, religious, and traditional associations of colors.Question 2 options:TrueFalseSave
Question 3 (1 point)
Tertiary colors are:Question 3 options:Three colors (any set of three colors) that appear next to each other on the color wheelTwo colors which appear directly opposite each other on the color wheelFormed when primary and secondary colors are mixedFormed when four colors appear next to each other on the color wheelSave
Question 4 (1 point)
To create a master slide, you need to find the Slide Master icon under the View tab.Question 4 options:TrueFalseSave
Question 5 (1 point)
You can easily move your PowerPoint slides by choosing the Slide view or the Outline view. You need to drag and drop a slide to the page you want it to be.Question 5 options:TrueFalseSave
Assignment: Psychological symbolism
Immunotherapy has made strides in being able to
In order to make the progress needed to impact the early diagnosis of AD, funding is required to provide the support needed to conduct early studies on those who show a high probability of being affected by the disease as early as 10 years prior to symptoms being noticed. Lesions are detectable which can identify those who are at risk for developing AD as early as 10 years prior to the development of symptoms through the increase of lesions which develop before measurable cognitive impairments are detectable, (Pesini et al., 2012).
In order to accomplish the goal of identifying biomarkers which would increase the ability to determine if a person is of higher risk for developing the disease, it is important to identify the right subject for the study to aids in providing more accuracy of the data collected (Pesini et al., 2012). Providing more accurate information based on biomarkers and risk factors, will help with the selection of AD partners to participate in clinical trials.
These trials would assist with the evaluation and creation of new therapies specifically for amyloid-targeting drugs and vaccines (Pesini et al., 2012). The article by Pesini et al., (2012) provides clarification of the ability to identify the lesions which can appear over the course of many years prior to the development of the disease.
Assignment: Psychological symbolism
Histopathological hallmarks referred to as hyperphosphorylated tau protein, create signs referred to as neurofibrillary tangles. These biomarkers provide accurate information regarding the likelihood of the individual being diagnosed with AD in the future.
Introduction of histopathological hallmarks of AD is senile plaques and neurofibrillary tangles, (Cedarbaum, Crans, and Grundman, 2010). It has been determined that the development of these lesions may develop over the course of many years before cognitive impairment which can be measured may be detected. The clinical course of Alzheimer’s disease (AD) can be seen as the progress from normal cognition, to Mild Cognitive Impairment (MCI) and to dementia. Clinical processes that utilize both clinical and biomarker information can aid in the early identification of AD patients and potentially those who are at risk of developing the disease, (Cedarbaum, Crans, & Grundman, 2010).
At this time, anti-amyloid immunotherapy is in a position to be the first to test the amyloid hypothesis for the treatment of AD. In contrast to the early predictions regarding the memory decline related to inflammation, the vaccine used which protected amyloid depositing mice from developing memory deficits showed positive results and that further studies were able to confirm that passive immunization could reverse deficits. These findings were encouraging and supported the trial of an A? vaccination in Alzheimer patients. While the trial was cut short due to meningoencephalitis symptoms in 6% of patients, a subclass of patients, who had developed brain-reactive antibodies showed slower rates of cognitive decline, (Morgan, 2006). Proposed changes for future studies would include steroidal therapy to avoid this in the future, as this was administered and those patients recovered. (Morgan, 2006)
Significance
The proposed research will aid in the understanding and early detection of those at risk for developing AD. Having the ability to fund studies which can provide early detection methods will allow clinicians the ability to diagnose and treat the disease early in the developmental stages before the decline of cognitive abilities begins. It will also allow the potential of finding a cure.
This particular study would be presented as a double-blind study to avoid influencing the data analysis and results by preventing the clinicians and participants from knowing who was provided a placebo vs the real medication. This would require the use of a controlled sample group who would receive ongoing care at a small facility in the beginning and expand during each phase of the program. Each group would be provided the drug designed to stop or slow the growth of the amyloid-plaque, which is taken orally and numerically assigned, based on the test group allocations. Each dose would be administered and would then be tracked numerically for cases of emergency or data collection later. The main goal of this approach is to solve questions related to the brain and the complexity of what causes the debilitating condition such as Alzheimer’s when it cannot be resolved solely by looking at the molecular structure and biology of genes/DNA.
It has been determined that an estimated 1 percent or less of all Alzheimer’s patients is the result of three specific genes which have been found to be hereditary, (Bekris, Bird, Tsuang, 2010). This is created by a genetic mutation caused by abnormalities of the chemical make-up in the genes. These are mutations involving the amyloid precursor protein (APP) and both the presenilin 1 and presenilin 2 proteins.
According to Goldman, Hahn, and Bird, N.D., those inheriting an Alzheimer’s mutation to the APP or presenilin 1 gene provide a high probability of developing the disease. Those inheriting an Alzheimer’s mutation to the presenilin 2 gene have a 95 percent chance of developing the disease (Goldman JS, Hahn SE, Bird T., N.D.). Because individuals with these mutations can show signs as early as 30 years of age, early diagnosis is critical to the treatment of Alzheimer’s disease especially as a result of these genetically altered genes. Early identification of those most likely to suffer from the decline in cognitive functions related to AD is needed to further progress in its treatment and an eventual cure. If this theory is proven, further studies will be expanded by longitudinal study of the same participants over the course of the next 3-5 years.
The traditional case studies often show disregard to the connection of in-clinical heterogeneity in AD, causing preclinical neuropathology to go unnoticed. For this reason, it is critical that biologically relevant markers are identified and that vivo surrogates of AD pathology would be considered extremely important to the progress which could be made, Ashton, N. J. (2017). In order to continue the progress made to date, more funding is needed in the specific areas which identify early signs. This will allow more time to observe the progression of the disease on participants during trials to determine if current approaches are slowing the progression of the disease.
Progress made would have a monumental impact on other neurophysiological disorders related to AD as well by opening doors to other conditions which show a cognitive decline in the sample study. The participants who may not develop either AD may exhibit other cognitive disorders within the sample group which can be researched as well in the developmental stages of these conditions. Other conditions which show similarities are vitamin deficiencies to the side effects of drugs. The proposed research will work with the Alzheimer’s and dementia research team of Alz Company to determine the long-term research needed at the Neurological Alz Center at Alz Dem University.
The successful development of AD treatment drugs requires more development. What is needed is a more methodical approach to drug development which can aid in reducing the high rate of negative trials. The lessons learned from trials with negative outcomes can provide better drug development, preclinical models of AD, dose-response, including a more accurate diagnosis using biomarkers, (Cummings, 2018). In order to confirm or refute the neurological effects of AD, the biomarkers would focus on the ability of participants to control attention to difficult issues, memory and theoretical reasoning.
In conclusion, being able to identify biomarkers early, which are consistent with the amyloid-precursor, senile plaques and neurofibrillary tangles, aid in early identification of those at risk for developing AD.